Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria

@article{Rabbani2011EffectOI,
  title={Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria},
  author={Naila Rabbani and Antonysunil Adaikalakoteswari and Kasper Rossing and Peter Rossing and Lise Tarnow and Hans-Henrik D. Parving and Paul J Thornalley},
  journal={Amino Acids},
  year={2011},
  volume={42},
  pages={1627-1639}
}
The aim of this study was to assess the effect of the angiotensin II receptor blocker Irbesartan on protein damage by glycation, oxidation and nitration in patients with type 2 diabetes and microalbuminuria. In a double-masked randomised crossover trial of 52 hypertensive type 2 diabetic patients, antihypertensive treatment was replaced with bendroflumethiazide. After 2-months wash-out, patients were treated randomly with Irbesartan 300, 600, and 900 mg o.d., each dose for 2 months in a three… Expand
Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes
TLDR
The effects observed point to the possibility that patients who have efficient mechanisms of disposal of damaged proteins might be at an increased risk of developing microalbuminuria but not early renal function decline, and support the concept that the mechanisms responsible for micro albuminuria may differ from the mechanisms involved in the initiation of early renalfunction decline. Expand
Increased DNA Dicarbonyl Glycation and Oxidation Markers in Patients with Type 2 Diabetes and Link to Diabetic Nephropathy
TLDR
DNA oxidative and glycation damage-derived nucleoside adducts are increased in plasma and urine of patients with type 2 diabetes and further increased in patients with diabetic nephropathy. Expand
Effect of metformin treatment in patients with type 2 diabetes with respect to glyoxalase 1 activity in atherosclerotic lesions.
TLDR
Treatment with metformin in patients with type 2 diabetes is associated with enhanced GLO1-activity in atherosclerotic lesions and correlated positively with increasing HbA1c, especially under meetformin treatment. Expand
Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
TLDR
Protein glycation biomarkers are influenced by heritability, aging, decline in metabolic, vascular, renal and skeletal health, and other factors, and are applicable to populations of differing ethnicities, bridging the gap between genotype and phenotype. Expand
The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients
TLDR
The ratio of AGE to sRAGE may be a surrogate biomarker for microvascular injury in hypertensive patients and further prospective studies of the prognostic value of the ratio in relation to microvasular injury are needed. Expand
Hidden Complexities in the Measurement of Fructosyl-Lysine and Advanced Glycation End Products for Risk Prediction of Vascular Complications of Diabetes
TLDR
Liquid chromatography-tandem mass spectrometry revealed two major forms of each AGE: AGE moieties of proteins, called AGE residues by conventional biochemical nomenclature and AGE free adducts formed mainly by the proteolysis of AGE-modified proteins. Expand
Advanced glycation end products in the pathogenesis of chronic kidney disease.
TLDR
The receptor for A GEs, RAGE, is important in development of CKD, but its interaction with AGEs in vivo remains enigmatic; other ligands and ternary complexation may be influential. Expand
Glycation- and/or Polyol pathway-inducing complications
Glycation of proteins by glucose forms fructosamine residues. Glycated hemoglobin “A1C” thereby formed is an indicator of glycemic control in diabetes and a marker for diagnosis of diabetes andExpand
Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications.
TLDR
This review aims at summarizing the mechanisms of AGEs formation and accumulation, and the most relevant issues in pre-clinical and clinical experiences in anti-AGEs treatment in cardiovascular research. Expand
Glycation of LDL by Methylglyoxal Increases Arterial Atherogenicity
TLDR
MG modification of LDL forms small, dense LDL with increased atherogenicity that provides a new route to atherogenic LDL and may explain the escalation of cardiovascular risk in diabetes and the cardioprotective effect of metformin. Expand
...
1
2
...

References

SHOWING 1-10 OF 40 REFERENCES
Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension
TLDR
Irbesartan did not alter the increase in pentosidine and CML in serum of type 2 diabetic patients with progressive nephropathy, suggesting that angiotensin receptor blockade alone is insufficient to reduce serum levels of AGEs in diabetic nephrostathy. Expand
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
TLDR
Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg. Expand
Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria
TLDR
Irbesartan (300 mg once daily) reduces low-grade inflammation in this high-risk population, and this may reduce the risk of micro- and macrovascular disease. Expand
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
TLDR
Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug. Expand
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
TLDR
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes. Expand
Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes
TLDR
AGEs, particularly arginine-derived hydroimidazolones, accumulate at sites of microvascular complication development and have markedly increased urinary excretion rates in experimental diabetes. Expand
Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic Patients
TLDR
This study confirms an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial function and inflammation, suggesting oxidative stress as a common mediator of such an effect. Expand
Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes
TLDR
There are profound increases in proteolytic products of glycated and oxidised proteins in diabetic patients, concurrent with much lower increases in protein glycation and oxidation adduct residues. Expand
Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function.
TLDR
This study shows that the acute loss of renal function and urinary excretion leads to the accumulation of AGE, oxidation, and nitration free adducts in the plasma. Expand
Renal handling of glycated albumin in non-insulin-dependent diabetes mellitus with nephropathy.
TLDR
The results suggested that early diabetic nephropathy which cannot be detected clinically by albuminuria can be diagnosed by measurement of renal selectivity for glycated albumin. Expand
...
1
2
3
4
...